期刊文献+

慢性阻塞性肺疾病患者痰中TNF-α及其受体水平与气流受限的关系 被引量:6

Change of Induced Sputum TNF-α and Its Receptors Levels in Patients with Acute Exacerbations of COPD
下载PDF
导出
摘要 【目的】观察慢性阻塞性肺疾病急性加重期(AECOPD)患者治疗前后气道内炎性介质与抗炎介质水平变化,阐明COPD气道局部炎症与气流受限的关系。【方法】检测48例COPD急性加重期患者入院时(A1组)及治疗1周后(A2组)诱导痰肿瘤坏死因子α(TNF-α)和可溶性肿瘤坏死因子受体55、75(sTNF-R55、sTNF-R75)的水平并进行肺功能测定。以28例健康志愿者(吸烟者,B1组;不吸烟者,B2组)为对照组进行分析治疗前后炎症因子及肺功能变化。【结果】AECOPD治疗前后诱导痰中TNF-α和sTNF-R55、sTNFR75的水平均高于健康组(P<0.01)。治疗后诱导痰中TNF-α浓度较入院时明显下降[A2组(478±266)pg/mLvsA1组(820±343)pg/mL,P<0.001];sTNF-R55浓度明显上升[A2(4.0±1.9)ng/mLvsA1(3.4±1.4)ng/mL,P<0.05),sTNFR75水平亦有所升高。AECOPD患者TNF-α浓度与FEV1、FEV1%pre呈负相关(rTNF-α分别-0.524、-0.490,P<0.01),而sTNF-R55和sTNF-R75水平均与FEV1、FEV1%pre、FEV1/FVC呈正相关(rsTNF-R55分别为0.547、0.312、0.220,P<0.001;rsTNF-R75分别为0.626、0.436、0.273,P<0.01)。对照组吸烟者TNF-α水平高于不吸烟者,且B1、B2组各细胞因子水平与肺功能无明显相关性。【结论】AECOPD患者气道内存在炎性介质与抗炎介质失衡,治疗后sTNF-R55水平上升,TNF-α水平降低,两者重新趋于平衡。抗炎介质水平的增加可能有利于临床肺功能的改善。 [Objective] The objective of this study was to determine the changes in inflammatory and anti-inflammatory mediator levels in patients with acute exacerbations of chronic obstructive pulmonary disease (AECOPD) before and after treatment, and clarify the relationship between local airway inflammation and airway obstruction in COPD. [Methods] Lung functions and tumor necrosis factor-α (TNF-α) and soluble TNF receptor (sTNF-R55 and sTNF-R75) levels of induced sputum were examined in 48 AECOPD patients on admission (group A1) and treatment day 7 (group A2). Twenty-eight healthy volunteers' samples served as controls (smokers as group B1, nonsmokers as group B2). The relationships between the changes in mediator levels and the AECOPD patients' lung functions before and after treatment were analyzed. [Results] Pre-and post-treatment TNF-α, sTNF-R55, and sTNFR75 levels were higher in patients' sputum than in controls. TNF-α levels decreased (478 pg/mL ± 266 pg/mL vs 820 pg/mL ± 343 pg/mL in group A1, P〈0.001); sTNF-R55 levels increased (4.0 pg/mL ± 1.9 ng/mL in group A2 vs 3.4 pg/mL ± 1.4 ng/mL in group A1, P 〈 0.05), and sTNF-R75 levels tended to increase after treatment. TNF-α levels correlated negatively with FEV1 and FEV1%pre (rTNF-α=-0.524,-0.490 respectively, P 〈 0.01); sTNF-R55 and sTNF-R75 levels correlated positively with FEV1, FEV1%pre, FEV1/FVC (rsTNF-R55=0.547, 0.312, 0.220 respectively, P 〈 0.001; rsTNF-R75=0.626, 0.436, 0.273, respectively, P 〈 0.01). Among controls, smokers had higher TNF-α levels than nonsmokers but lung functions and mediator levels were unrelated in controls. [Conclusion] Inflammatory and anti-inflammatory mediators were imbalanced in AECOPD patients' airways. After treatment, TNF-α levels decreased, sTNF-R55 levels increased and they tended to balance again. The increase of anti-inflammatory mediators had a possibly beneficial effect with respect to lung function improvement.
出处 《中山大学学报(医学科学版)》 CAS CSCD 北大核心 2008年第1期82-86,共5页 Journal of Sun Yat-Sen University:Medical Sciences
基金 广东省自然科学基金项目(04009385) 广东省卫生厅基金项目(A2004188)
关键词 阻塞性 肺疾病 诱导痰 肿瘤坏死因子α 可溶性肿瘤坏死因子受体 obstructive pulmonary disease induced sputum tumor necrosis factor-α soluble tumor necrosis factor receptor
  • 相关文献

参考文献10

  • 1Fabbri LM, Hrud SS. GOLD Scientific Committee. Global Strategy for the Diagnosis, Management, and Prevention of COPD 2003 Update [J]. Eur Resp J, 2003,22( 1 ) : 1-2.
  • 2Dentener MA, Creutzberg EC, Schols AM, et al. Systemic anti-inflammatory mediators in COPD: increase in soluble interleukin 1 receptor Ⅱ during treatment of exacerbations [J]. Thorax, 2001,56(9) : 721-726.
  • 3Hale KK, Snith CG, Baker SL, et al. Muhifunctional regulation of the biological effects of TNF-alpha by the soluble type Ⅰ and type Ⅱ TNF receptors [J]. Cytokine, 1995,7(1 ) : 26-38.
  • 4Celli BR, Macnee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper [J]. Eur Respir J, 2004,23 (6) : 932-946.
  • 5Bach PB, Brown C, Gelfand SE, et al. Management of aute exacerbations of chronic obstructive pulmonary disease: A summary and appraisal of published evidence [J]. Ann Inter Med, 2001,134(7):600-620.
  • 6曾勉,吴健锋,谢灿茂,严英硕,陈冬梅,禤建美.慢性阻塞性肺疾病急性加重期患者规范化痰诱导安全性的初步研究[J].中华结核和呼吸杂志,2005,28(4):238-241. 被引量:45
  • 7曾勉,刘凌云,张式鸿,谢灿茂,王辉,黄晓梅.各期慢性阻塞性肺疾病患者诱导痰细胞成分与肺功能的关系[J].中山大学学报(医学科学版),2007,28(4):422-425. 被引量:26
  • 8Vemooy JH, Kucukaycan M, Jacobs JA, et al. Local and systemic inflammation in patients with chronic obstructive pulmonary disease:Soluble tumor necrosis factor receptors are increased in sputum [J].Am J Respir Crit Care Med, 2002, 166(9) : 1218-1224.
  • 9Takenura M, Saito K, Seishima M. Soluble tumor necrosis factor receptor Ⅰ,Ⅱ [J]. Nippon Rinsho, 2005,63 Suppl 8 : 158-160.
  • 10Takabatake N, Nakamura H, Abe S, et al. Circulating leptin in patients with chronic obstructive pulmonary disease [J]. Am J Respir Crit Care Med, 1999,159(4 pt 1 ) : 1215-1219.

二级参考文献22

  • 1曾勉,吴健锋,谢灿茂,严英硕,陈冬梅,禤建美.慢性阻塞性肺疾病急性加重期患者规范化痰诱导安全性的初步研究[J].中华结核和呼吸杂志,2005,28(4):238-241. 被引量:45
  • 2Pin I,Gibson PG,Kolendowicz R,et al. Use of induced sputum cell counts to investigate airway inflammation in asthma. Thorax,1992,47:25-29.
  • 3Sutherland ER,Pak J,Langmack EL,et al. Safety of sputum induction in moderate-to-severe chronic obstructive pulmonary disease. Respir Med,2002,96:482-486.
  • 4Fabbri LM,Hurd SS,GOLD Scientific Committee. Global strategy for the diagnosis,management and prevention of COPD:2003 update. Eur Respir J,2003,22:1-2.
  • 5Celli BR,MacNee W, ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD:a summary of the ATS/ERS position paper. Eur Respir J,2004,23:932-946.
  • 6Bach PB,Brown C,Gelfand SE,et al. Management of acute exacerbations of chronic obstructive pulmonary disease:a summary and appraisal of published evidence. Ann Intern Med,2001,134:600-620.
  • 7Vignola AM,Rennar SI,Hargreave FE,et al. Standardised methodology of sputum induction and processing. Future directions. Eur Respir J Suppl,2002,37:51s-55s.
  • 8Tsoumakidou M,Tzanakis N,Siafakas NM. Induced sputum in the investigation of airway inflammation of COPD. Respir Med,2003,97:863-871.
  • 9Vlachos-Mayer H,Leigh R,Sharon RF,et al. Success and safety of sputum induction in the clinical setting. Eur Respir J,2000,16:997-1000.
  • 10Rohde G,Wiethege A,Borg I,et al. Respiratory viruses in exacerbations of chronic obstructive pulmonary disease requiring hospitalisation:a case-control study. Thorax,2003,58:37-42.

共引文献61

同被引文献72

引证文献6

二级引证文献95

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部